Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HINT1 | P49773 | 4/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 2/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25408283 | 0.93 | HINT1 (0.56) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL3969244 | 0.92 | HINT1 (0.56) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL5661895 | 0.89 | HINT1 (0.55) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL12300426 | 0.89 | HPGD (0.61) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL16198946 | 0.89 | HPGD (0.61) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL16360143 | 0.89 | HPGD (0.61) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL3713950 | 0.89 | HPGD (0.61) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL26515 | 0.89 | HPGD (0.61) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL18512866 | 0.89 | HPGD (0.61) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL12031119 | 0.89 | HPGD (0.61) | HPGDHINT1NT5EGSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319916-B2 | Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs | CAMP4 THERAPEUTICS CORPORATION (US) | 2025-06-03 | — | — | US | claimed |
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | claimed |
| US-20240336924-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2024-10-10 | — | — | US | claimed |
| EP-4741411-A2 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-20260103714-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA AS (DK) | 2026-04-16 | — | — | US | disclosed |
| EP-4720283-A1 | OLIGONUCLEOTIDES TARGETING GAL3ST1 | Contera Pharma A/S (DK) | 2026-04-08 | — | — | EP | disclosed |
| EP-4594491-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | Contera Pharma A/S (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-20250188477-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| WO-2025110249-A1 | COMPOSITION FOR NUCLEOTIDE SEQUENCE EDITING, AND NUCLEOTIDE SEQUENCE EDITING METHOD USING SAME | 国立大学法人 広島大学 | 2025-05-30 | — | — | WO | disclosed |
| US-20250122505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2025-04-17 | — | — | US | disclosed |
| US-20070082861-A1 | Ena nucleic acid drugs modifying splicing in mrna precursor | MASAFUMI MATSUO (JP) | 2007-04-12 | — | — | US | disclosed |
| EP-1568769-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | Matsuo, Masafumi (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1019539-A4 | COMBINATORIAL ANTISENSE LIBRARY | GEN PROBE INC (US) | 2005-03-09 | — | — | EP | disclosed |
| US-6762169-B1 | IMPROVED TRANSMEMBRANE DELIVERY OF NUCLEOSIDES CONJUGATED TO AN ARYLPROPIONIC ACID LIGAND (IBUPROFEN) WHICH HAS AFFINITY FOR PLASMA PROTEIN ALBUMIN; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. | 2004-07-13 | — | — | US | disclosed |
| US-6656730-B1 | Attached to an arylpropionic acid that interacts with human serum albumin; acid is ibuprofen, suprofen, ketoprofen, (S)-(+)- pranoprofen, or carprofen. | ISIS PHARMACEUTICALS, INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1185305-A1 | LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000076554-A1 | LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-1019539-A1 | COMBINATORIAL ANTISENSE LIBRARY | Oasis Biosciences, Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999018238-A1 | COMBINATORIAL ANTISENSE LIBRARY | OASIS BIOSCIENCES, INC. (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336924-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CPS1, CTPS1, CTPS2 | HPGD 4328/4885HINT1 1282/4885NT5E 2363/4885 |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | TFRC, FOLR2, FTH1 | HPGD 4840/4885HINT1 3720/4885NT5E 2227/4885 |
| US-12319916-B2 | Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs | CPS1, CTPS1, CTPS2 | HPGD 4328/4885HINT1 1282/4885NT5E 2363/4885 |
| US-20260103714-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | NAT10, NAT1, NAA40 | HPGD 4533/4885HINT1 540/4885NT5E 767/4885 |
| US-20250122505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | HPGD 4350/4885HINT1 1092/4885NT5E 2411/4885 |
| US-20070082861-A1 | Ena nucleic acid drugs modifying splicing in mrna precursor | SNRPA, RBM17, SNRPA1 | HPGD 2583/4885HINT1 2656/4885NT5E 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.